Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.
Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.
Read more
Project ALS & the Robert Packard Center for ALS Research present Challenges & Opportunities of ALS Modeling
Packard Center and Project ALS host workshop to share knowledge on culturing human neurons as an essential research tool From April 28–30, more than forty
July 9, 2025
No Comments
